Sales Nexus CRM

D. Boral Capital LLC Facilitates $22 Million Offering for Omeros Corporation

By Advos

TL;DR

Omeros Corporation secured a 14% premium in its recent offering, leveraging D. Boral Capital's expertise to raise $22 million, showcasing strategic financial advantage.

D. Boral Capital facilitated Omeros Corporation's registered direct offering, selling 5,365,853 shares at $4.10 each under a Form S-3 shelf registration.

This capital raise by Omeros Corporation, supported by D. Boral Capital, fuels innovation in healthcare, potentially improving patient outcomes globally.

Discover how Omeros Corporation's $22 million raise at a premium highlights the dynamic interplay between biotech firms and investment banks like D. Boral Capital.

Found this article helpful?

Share it with your network and spread the knowledge!

D. Boral Capital LLC Facilitates $22 Million Offering for Omeros Corporation

D. Boral Capital LLC, a New York-based global investment bank, recently served as the exclusive placement agent for Omeros Corporation's (NASDAQ: OMER) $22 million registered direct offering. The transaction, which closed on July 28, 2025, involved the sale of 5,365,853 shares of common stock at $4.10 per share, marking a 14% premium over the closing price on the date of the securities purchase agreement. This strategic move underscores the confidence of investors like Polar Asset Management Partners in Omeros' potential and D. Boral Capital's capability to secure substantial investments for its clients.

The offering was conducted under a 'shelf' Registration Statement on Form S-3, showcasing a streamlined approach to raising capital that benefits both the company and its investors. For more details on the offering, visit https://ibn.fm/rYKQL. This transaction not only provides Omeros with the necessary funds to advance its research and development efforts but also highlights D. Boral Capital's expertise in navigating the complex landscape of biotech financing.

D. Boral Capital's successful aggregation of approximately $30 billion in capital since its inception in 2020, through around 350 transactions, positions it as a key player in the investment banking sector. The firm's ability to deliver tailored financial solutions to middle-market and emerging growth companies across diverse sectors worldwide is a testament to its strategic advisory prowess. For more information about D. Boral Capital, visit https://dboralcapital.com/.

This offering is significant for the biotech industry, as it demonstrates the continued investor interest in funding innovative healthcare solutions. It also reflects the importance of specialized financial institutions like D. Boral Capital in facilitating these critical transactions, which can accelerate the development of new therapies and technologies. The successful closure of this offering may encourage other biotech firms to explore similar financing options, potentially leading to more advancements in the sector.

blockchain registration record for this content
Advos

Advos

@advos